ClinicalTrials.gg
CompletedNCT01772524Updated Jan 8, 2016

Safety, Efficacy and Pharmacokinetics of ALD403

A Phase 1 interventional study of ALD403 and Placebo in Migraine, sponsored by Alder Biopharmaceuticals, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-01-08.

Sponsored by Alder Biopharmaceuticals, Inc. (part of H. Lundbeck A/S) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing eptinezumab in Migraine Disorders — 6 open to participants now, 6 under way, 5 of them phase 3. eptinezumab · Migraine Disorders.

Enrollment
13th of 21
163 · median 193
Started
2013
the only one that year
Phase 1
3 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
6 of 21
Alder Biopharmaceuticals, Inc.

Among the 21 studies testing eptinezumab in Migraine Disorders, this one is the 13th largest by enrollment, is the only one that started in 2013, is one of 3 in phase 1, and was the 2nd registered.

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

Browse Migraine Disorders studies →

Open to participants now

6 of the 21 studies testing eptinezumab in Migraine Disorders are open now, in 11 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About eptinezumab

eptinezumab: first FDA approval 2020 (VYEPTI), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 217 Migraine Disorders studies recruiting now, 66 (30%) set no upper age limit and 136 (63%) stop at 75 or younger; 44 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing eptinezumab in Migraine Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, pharmacokinetics and efficacy of a single dose of ALD403 in the prevention of migraine headache in frequent episodic migraineurs for 24 weeks.

03

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Migraine Disorders
  • Phase 1
  • ALD403
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of migraine at ≤ 50 years of age (ICHD-II, 2004 Section 1)
  • History of migraine ≥ 12 months with

    • ≥ 5 and ≤ 14 migraine days in each 28 day period in the 3 months prior to screening
    • use of acute migraine medications ≤ 14 days per 28 day period and, within those days, ≤ 10 days of triptan use per 28 day period in the 3 months prior to screening and the 28 day period of completion of eDiary prior to randomization
  • Women of and males with partners of child-bearing potential must agree to use adequate (oral or injectable [depot] estrogen, and/or progestogen, or selective estrogen receptor modulator contraceptive therapeutic, intrauterine contraceptive device, or double barrier method [e.g., condom and diaphragm or spermicidal gel]). Non-childbearing potential is defined as for at least 1 year or surgical sterilization or hysterectomy at least 3 months before screening
  • Any hormonal therapy (e.g., oral contraceptives, hormone replacement therapy) use is stable and ongoing for at least 3 months prior to screening and during the 28 day period from screening to randomization
  • Agree not to post any personal medical data related to the trial or information related to the trial on any website or social media site (e.g., Facebook, Twitter) until the trial has been completed

Exclusion criteria

Exclusion Criteria

  • Confounding pain syndromes including fibromyalgia, chronic musculoskeletal (e.g., low back pain), psychiatric conditions, dementia, or major neurological disorders other than migraine that interfere with the participation in the trial
  • Diagnosis of complicated migraine, chronic tension-type headache, hypnic headache, hemicrania continua, new daily persistent headache, basilar, hemiplegic, or familial hemiplegic migraine
  • Regular use (greater than 7 days) of prophylactic headache medication (any preventive medication or supplement with evidence of efficacy from at least 1 placebo-controlled trial) within 3 months, or onabotulinumtoxin A within 6 months prior to screening or during the 28 day period prior to randomization
  • Cardiac surgery or cardiac symptoms within 3 months of screening and during the 28 day period prior to randomization
  • Suspected or diagnosis of hypertension with or without antihypertensive treatment
  • Any ongoing co-morbidity that in the opinion of the Investigator will interfere with the participation in the trial
  • (BMI) > 39 at screening
  • Pregnant, breast-feeding, or planning to become pregnant during the trial
  • Patients who have used opioids > 5 days for the treatment of pain in more than 2 of the 6 months prior to screening or in the 28 day period prior to randomization
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    ALD403

    Single IV Dose on Day 0

    Biological: ALD403

  • Placebo comparator
    Saline

    Single IV infusion on Day 0

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of ALD403: laboratory variables, ECG and adverse events

    * Physical Examination * Vital signs * 12-lead ECG (electrocardiogram) * Clinical laboratory tests (hematology, chemistry) * Number of participants with Adverse Events

    Time frame: 24 weeks

Secondary outcomes

  1. Evaluation of Pharmacokinetics of ALD403

    * Cmax - maximum plasma concentration * Tmax - Time to achieve maximum plasma concentration * AUC - Area under the plasma concentration-time curve * T1/2 - Elimination half-life * Vz - Volume of distribution * CL - Clearance * Bioavailability * Plasma levels of unbound ALD403

    Time frame: 24 weeks

  2. Efficacy of ALD403

    * Change in frequency of migraine days compared to baseline * Responder rate * Migraine hours * Migraine episodes * Migraine severity * Use of acute migraine medications

    Time frame: 12 weeks

07

Study locations

26 sites
  • Premiere Research
    Phoenix, Arizona 85027, United States
  • ACT Trials
    Anaheim, California 92801, United States
  • Collaborative Neuroscience Network, Inc.
    Long Beach, California 90806, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • San Francisco Clinical Research
    San Francisco, California 94109, United States
  • CA Medical Clinic for Headache
    Santa Monica, California 90404, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • MD Clinical
    Hallandale Beach, Florida 33009, United States
  • Miami Research
    Miami, Florida 33143, United States
  • Segal Institute for Clinical Research
    North Miami, Florida 33161, United States
  • Palm Beach Research Center
    West Palm Beach, Florida 33409, United States
  • Boston Clinical Trials
    Roslindale, Massachusetts 02131, United States
  • MedVadis Research
    Watertown, Massachusetts 02472, United States
  • Michigan Headache & Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinvest
    Springfield, Missouri 65807, United States
  • SPRI
    Brooklyn, New York 11235, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • Wake Research
    Raleigh, North Carolina 27612, United States
  • Community Research
    Cincinnati, Ohio 45255, United States
  • Coastal Carolina Research Center
    Mt. Pleasant, South Carolina 29464, United States
  • ClinSearch
    Chattanooga, Tennessee 37421, United States
  • Neurology Associates of Arlington
    Arlington, Texas 76017, United States
  • Premiere Research
    Austin, Texas 78705, United States
  • CRI Lifetree
    Salt Lake City, Utah 84106, United States
  • Tidewater Integrated Medical Research
    Virginia Beach, Virginia 23454, United States
  • Seattle Women's: Health, Research, Gynecology
    Seattle, Washington 98105, United States
08

References and documents

Publications

  • Smith TR, Spierings ELH, Cady R, Hirman J, Ettrup A, Shen V. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies. J Headache Pain. 2021 Nov 25;22(1):143. doi: 10.1186/s10194-021-01360-1. PubMed 34823467 ↗
  • Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen MK, Brunner E, Honeywell L, Mehta L. Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials. J Headache Pain. 2021 Mar 30;22(1):16. doi: 10.1186/s10194-021-01227-5. Erratum In: J Headache Pain. 2021 May 25;22(1):46. doi: 10.1186/s10194-021-01253-3. PubMed 33781209 ↗
  • Dodick DW, Goadsby PJ, Silberstein SD, Lipton RB, Olesen J, Ashina M, Wilks K, Kudrow D, Kroll R, Kohrman B, Bargar R, Hirman J, Smith J; ALD403 study investigators. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol. 2014 Nov;13(11):1100-1107. doi: 10.1016/S1474-4422(14)70209-1. Epub 2014 Oct 5. PubMed 25297013 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Dec 2013 and a completion of Feb 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2013
First posted
Jan 21, 2013
Start
Jan 2013
Primary completionActual
Dec 2013
CompletionActual
Feb 2014
Last update
Jan 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01772524
Responsible party
Sponsor
First posted
Jan 21, 2013
Start date
Jan 2013
Primary completion
Dec 2013
Completion
Feb 2014
Last update
Jan 8, 2016

Study contacts

Jeff Smith, MD
study director · Alder Biopharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eptinezumab

Start the discussion